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Abstract
We consider a recent coinfection model for Tuberculosis (TB), Human
Immunodeficiency Virus (HIV) infection and Acquired Immunodeficiency
Syndrome (AIDS) proposed in [Discrete Contin. Dyn. Syst. 35 (2015),
no. 9, 4639–4663]. We introduce and analyze a multiobjective formula-
tion of an optimal control problem, where the two conflicting objectives
are: minimization of the number of HIV infected individuals with AIDS
clinical symptoms and coinfected with AIDS and active TB; and costs
related to prevention and treatment of HIV and/or TB measures. The
proposed approach eliminates some limitations of previous works. The
results of the numerical study provide comprehensive insights about the
optimal treatment policies and the population dynamics resulting from
their implementation. Some nonintuitive conclusions are drawn. Over-
all, the simulation results demonstrate the usefulness and validity of the
proposed approach.
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1 Introduction
The human immunodeficiency virus (HIV) is a retrovirus that infects cells of
the immune system, destroying or impairing their function. HIV is transmit-
ted primarily via unprotected sexual intercourse, contaminated blood trans-
fusions, hypodermic needles, and from mother to child during pregnancy, de-
livery, or breastfeeding [23]. As the infection progresses, the immune system
becomes weaker, and the person becomes more susceptible to infections. The
most advanced stage of HIV infection is acquired immunodeficiency syndrome
(AIDS) [29]. There is no cure or vaccine to AIDS. However, antiretroviral
(ART) treatment improves health, prolongs life, and substantially reduces the
risk of HIV transmission. In both high-income and low-income countries, the
life expectancy of patients infected with HIV who have access to ART is now
measured in decades, and might approach that of uninfected populations in pa-
tients who receive an optimum treatment (see [4] and references cited therein).
However, ART treatment still presents substantial limitations: does not fully
restore health; treatment is associated with side effects; the medications are ex-
pensive; and is not curative. Following the Joint United Nations Programme on
HIV and AIDS (UNAIDS), in 2013 there were approximately 35 million people
living with HIV globally. An estimated 2.1 million people became newly infected
with HIV in 2013, down from 3.4 million in 2001 worldwide. The number of
new HIV infection among children has declined 58% since 2001, being in 2013
approximately 240 000 worldwide. The number of AIDS-related deaths have
fallen by 35% since the peak in 2005. In 2013, approximately 1.5 million people
died from AIDS-related causes worldwide. In 2013, around 12.9 million people
living with HIV had access to ART therapy, which represents, approximately,
37% of all people living with HIV [26, 28].
Mycobacterium tuberculosis is the cause of most occurrences of tuberculosis
(TB) and is usually acquired via airborne infection from someone who has ac-
tive TB. It typically affects the lungs (pulmonary TB) but can affect other sites
as well (extrapulmonary TB). According with the World Health Organization
(WHO), in 2013, an estimated 9.0 million people developed TB and 1.5 million
died from the disease, 360 000 of whom were HIV-positive. TB is slowly declin-
ing each year and it is estimated that 37 million lives were saved between 2000
and 2013 through effective diagnosis and treatment. However, since most deaths
from TB are preventable, the death toll from the disease is still unacceptably
high and efforts to combat it must be accelerated [31].
Following WHO, the human immunodeficiency virus (HIV) and mycobac-
terium tuberculosis are the first and second cause of death from a single infec-
tious agent, respectively [30]. Both HIV/AIDS and TB are present in all regions
of the world [17, 31]. Individuals infected with HIV are more likely to develop
TB disease because of their immunodeficiency, and HIV infection is the most
powerful risk factor for progression from TB infection to disease [9]. In 2013, 1.1
million of 9.0 million people who developed TB worldwide were HIV-positive.
The number of people dying from HIV-associated to TB has been falling since
2003. However, there were still 360 000 deaths from HIV-associated to TB in
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2013, and further efforts are needed to reduce this burden [31]. ART is a critical
intervention for reducing the risk of TB morbidity and mortality among people
living with HIV and, when combined with TB preventive therapy, it can have
a significant impact on TB prevention [31]. Collaborative TB/HIV activities
(including HIV testing, ART therapy and TB preventive measures) are crucial
for the reduction of TB-HIV coinfected individuals. WHO estimates that these
collaborative activities prevented 1.3 million people from dying, from 2005 to
2012. However, significant challenges remain: the reduction of tuberculosis re-
lated deaths among people living with HIV has slowed in recent years; the ART
therapy is not being delivered to TB-HIV coinfected patients in the majority of
the countries with the largest number of TB/HIV patients; the pace of treat-
ment scale-up for TB/HIV patients has slowed; less than half of notified TB
patients were tested for HIV in 2012; and only a small fraction of TB/HIV in-
fected individuals received TB preventive therapy [27]. The study of the joint
dynamics of TB and HIV present formidable mathematical challenges due to
the fact that the models of transmission are quite distinct [22]. Here we focus on
a recent mathematical model of optimal control for TB-HIV/AIDS coinfection
proposed by [25].
Optimal control is a branch of mathematics developed to find optimal ways
to control a dynamic system [20], e.g. a dynamic system that models infectious
diseases. Optimal control has been applied to TB models, HIV models and also
co-infection models (see, e.g., [1, 11–14, 21, 24, 25] and references cited therein
for TB-HIV/AIDS models and [18] for co-infection of malaria and cholera).
In this paper we consider the optimal control problem for the TB-HIV/AIDS
model proposed in [25] from a multiobjective perspective. Our approach avoids
the use of weight parameters and allows to obtain a wide range of optimal
control strategies. These strategies offer the decision maker useful information
for effective decision making.
Traditional mathematical programming methods for solving multiobjective
optimization problems (MOPs) convert the original problem into a single-objective
optimization problem. This is referred as to scalarization and the function to be
optimized, which depends on some parameters, is termed the scalarizing func-
tion. A solution to the scalarizing function, obtained using a single-objective
optimization algorithm, is expected to be Pareto optimal. For approximating
multiple Pareto optimal solutions, repeated runs with different parameter set-
tings must be performed. The weighted sum method [8] consists in minimizing a
weighted sum of multiple objectives. For problems with a convex Pareto front,
this method guarantees finding solutions in the entire Pareto optimal region.
However, it fails to find solutions in nonconvex regions of the Pareto front.
Weighted metric methods [16] are based on minimizing a weighted distance be-
tween some reference point and the feasible objective region. The widely used
approach belonging to this class of methods is the Chebyshev method [2], which
consists in minimizing a weighted infinity norm. Although solutions in convex
and nonconvex regions of the Pareto front can be obtained by this method, a
resulting scalarizing function becomes nondifferentiable even when all the objec-
tives are differentiable. The problem resulting from the Chebyshev method can
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be reformulated in the smooth form. The resulting formulation is known as the
goal attainment method [16] or the Pascoletti–Serafini scalarization [19]. In this
method, a slack variable is minimized and the weighted difference for each ob-
jective is converted into a constraint. Although the problem can be solved in a
differentiable form, problem complexity is augmented by adding one additional
variable and m constraints (where m is the number of objectives). The normal
boundary intersection and normal constraint methods use a hyperplane with
uniformly distributed points passing through the critical points of the Pareto
front. The normal boundary intersection method [3] searches for the maximum
distance from a point on the simplex along the normal pointing toward the ori-
gin. The obtained point may or may not be a Pareto optimal point, with the
resulting scalarizing problem including an equality constraint that is not easy
to treat for all the cases. On the other hand, the normal constraint method [15]
uses an inequality constraint reduction of the feasible objective space and the
normalized function values to cope with disparate function scales. The method
is successful in achieving a uniform distribution of approximating points, though
there is no guarantee that an obtained point is Pareto optimal. Here, motivated
by the results recently obtained in [7] for a TB model and in [5,6] for the dengue
disease, we adopt the ǫ-constraint method [10]. This method suggests optimiz-
ing one objective function and converting all other objectives as constraints,
setting an upper bound to each of them. Solutions obtained using multiobjec-
tive optimization provide comprehensive insights about the optimal strategies
and the diseases dynamics resulting from implementation of those strategies.
The paper is organized as follows. In Section 2 we briefly describe the TB-
HIV/AIDS model from [25]. The multiobjective optimization theory is applied
to an optimal control problem in Section 3: we start by formulating the optimal
control problem in Subsection 3.1, then we consider this problem from a mul-
tiobjective perspective (Subsection 3.2) and we describe the numerical method
that we use to solve the multiobjective problem (Subsection 3.3). In Section 4
we present and discuss numerical results for the multiobjective problem. We
end with Section 5 of conclusions and future work.
2 TB-HIV/AIDS coinfection model
The present study considers the population model for TB-HIV/AIDS coinfection
proposed in [25], where TB, HIV and TB-HIV infected individuals have access to
respective disease treatment, and single HIV-infected and TB-HIV co-infected
individuals under HIV and TB/HIV treatment, respectively, stay in a chronic
stage of the HIV infection. The model divides the population into eleven mutu-
ally exclusive compartments: susceptible individuals (S); TB-latently infected
individuals, who have no symptoms of TB disease and are not infectious (LT );
TB-infected individuals, who have active TB disease and are infectious (IT );
TB-recovered individuals (R); HIV-infected individuals with no clinical symp-
toms of AIDS (IH); HIV-infected individuals under treatment for HIV infection
(CH); HIV-infected individuals with AIDS clinical symptoms (A); TB-latent
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individuals co-infected with HIV (pre-AIDS) (LTH); HIV-infected individuals
(pre-AIDS) co-infected with active TB disease (ITH); TB-recovered individuals
with HIV-infection without AIDS symptoms (RH); and HIV-infected individu-
als with AIDS symptoms co-infected with active TB (AT ). The total population
at time t, denoted by N(t), is given by
N(t) = S(t) + LT (t) + IT (t) +R(t) + IH(t) +A(t) + CH(t)
+ LTH(t) + ITH(t) +RH(t) +AT (t).
Susceptible individuals acquire TB infection from individuals with active TB at
a rate λT , given by
λT (t) =
β1
N(t)
(IT (t) + ITH(t) +AT (t)),
where β1 is the effective contact rate for TB infection. Similarly, susceptible in-
dividuals acquire HIV infection, following effective contact with people infected
with HIV at a rate λH , given by
λH(t) =
β2
N(t)
[IH(t)+ ITH(t)+LTH(t)+RH(t)+ ηCCH(t)+ ηA(A(t)+AT (t))],
where β2 is the effective contact rate for HIV transmission, ηA ≥ 1 is the mod-
ification parameter that accounts for the relative infectiousness of individuals
with AIDS symptoms and ηC ≤ 1 is the modification parameter that translates
the partial restoration of immune function of individuals with HIV infection
that use correctly the antiretroviral treatment. The remaining parameters used
to describe the model are presented in Table 1.
Two control functions, which represent prevention and treatment measures,
are introduced into the model and are continuously implemented during a con-
sidered period of disease treatment: the control u1(t) represents the fraction
of ITH individuals that takes HIV and TB treatment, simultaneously; u2(t)
represents the fraction of ITH individuals that takes TB treatment only [25].
The transmission dynamics of TB-HIV/AIDS coinfection is modeled by the
following system of differential equations:


S˙(t) = µ− λT (t)S(t)− λH(t)S(t)− dNS(t),
L˙T (t) = λT (t)S(t) + γ1λT (t)R(t)− (k1 + τ1 + dN )LT (t),
I˙T (t) = k1LT (t)− (τ2 + dT + dN + δλH(t))IT (t),
R˙(t) = τ1LT (t) + τ2IT (t)− (γ1λT (t) + λH(t) + dN )R(t),
I˙H(t) = λH(t)S(t)− (ρ1 + φ+ ψλT (t) + dN)IH(t) + α1A(t) + λH(t)R(t) + ω1CH(t),
A˙(t) = ρ1IH(t) + ω2RH(t)− α1A(t)− (dN + dA)A(t),
C˙H(t) = φIH(t) + u1(t)ρ2ITH(t) + rk3LTH(t)− (ω1 + dN)CH(t),
L˙TH (t) = γ2λT (t)RH(t)− (k2 + k3 + dN)LTH(t),
I˙TH(t) = δλH(t)IT (t) + ψλT (t)IH(t) + α2AT (t) + k2LTH (t)− (ρ2 + dN + dT )ITH(t),
R˙H(t) = u2(t)ρ2ITH(t) + (1− r)k3LTH(t)− (γ2λT (t) + ω2 + dN)RH(t),
A˙T (t) = (1− (u1(t) + u2(t)))ρ2ITH(t)− (α2 + dN + dTA)AT (t).
(1)
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Symbol Description Value
T Considered time in years 10
N(0) Initial population size 30000
γ1 Modification parameter 0.9
γ2 Modification parameter 1.1
ηC Modification parameter 0.9
ηA Modification parameter 1.05
δ Modification parameter 1.03
ψ Modification parameter 1.07
β1 TB transmission rate 0.6
β2 HIV transmission rate 0.1
µ Recruitment rate 430.0
k1 Rate at which individuals leave LT class by becoming infectious 1.0/2.0
k2 Rate at which individuals leave LTH class by becoming TB infectious 1.3k1
k3 Rate at which individuals leave LTH class 2.0
ρ1 Rate at which individuals leave IH class to A 0.1
ρ2 Rate at which individuals leave ITH class 1.0
ω1 Rate at which individuals leave CH class 0.09
ω2 Rate at which individuals leave RH class 0.15
τ1 TB treatment rate for LT individuals 2.0
τ2 TB treatment rate for IT individuals 1.0
φ HIV treatment rate for IH individuals 1.0
α1 AIDS treatment rate 0.33
α2 HIV treatment rate for AT individuals 0.33
r Fraction of LTH individuals that take HIV and TB treatment 0.3
dN Natural death rate 1.0/70.0
dT TB induced death rate 1.0/10.0
dA AIDS induced death rate 0.3
dTA AIDS-TB induced death rate 0.33
Table 1: Model parameters, borrowed from [25].
The model flow is illustrated in Figure 1. The initial conditions are given in
Table 2. Note that the period spent in class ITH does not change with the control
measures because the controls represent the fraction of individuals that are
treated both for TB and HIV and only for TB, and not the treatment duration.
Indeed, the period spent in class ITH is given by the constant treatment rate
ρ2.
3 Multiobjective approach to an optimal control
problem
Traditionally, the problem of finding a control law for a given system is addressed
by optimal control theory [20].
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Figure 1: Model for TB-HIV/AIDS transmission.
3.1 Optimal control problem
In the optimal control approach, the aim is to find the optimal values u∗1 and
u∗2 of the controls u1 and u2, such that the associated state trajectories S
∗, L∗T ,
I∗T , R
∗, I∗H , A
∗, C∗H , L
∗
TH , I
∗
TH , R
∗
H , A
∗
T , are solution of system (1) in the time
interval [0, T ], with the initial conditions in Table 2, and minimize an objective
functional. Consider the state system of ordinary differential equations (1) and
the set of admissible control functions given by
Ω = {(u1(·), u2(·)) ∈ (L
∞(0, T ))2 | 0 ≤ u1(t), u2(t) ≤ 0.95
∧ u1(t) + u2(t) ≤ 0.95, ∀t ∈ [0, T ]}.
According to [25], the objective functional can be defined as
J(u1(·), u2(·)) =
∫ T
0
[
A(t) +AT (t) + w1u
2
1(t) + w2u
2
2(t)
]
dt, (2)
where the constants w1 and w2 are a measure of the relative cost of the inter-
ventions associated with the controls u1 and u2, respectively. Note that the
objective functional (2) is a function of state and control variables. Its mini-
mization implies three important aspects: (i) reducing the number of individu-
als with AIDS symptoms, (ii) decreasing the number of individuals with AIDS
symptoms and active TB disease and (iii) reducing the costs of implementing
treatment policies. The optimal control problem consists in determining (S∗,
L∗T , I
∗
T , R
∗, I∗H , A
∗, C∗H , L
∗
TH , I
∗
TH , R
∗
H , A
∗
T ), associated to admissible controls
(u∗1(·), u
∗
2(·)) ∈ Ω on the time interval [0, T ], satisfying (1), the initial conditions
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Cathegory Description Initial Value
S Susceptible 66N(0)
120
LT TB-Latent
37N(0)
120
IT TB-Active infected
5N(0)
120
R TB-Recovered 37N(0)
120
IH HIV-Infected (pre-AIDS)
2N(0)
120
A HIV-infected with AIDS symptoms 37N(0)
120
CH HIV-infected under ART therapy
N(0)
120
LTH TB-Latent co-infected with HIV (pre-AIDS)
2N(0)
120
ITH HIV-Infected (pre-AIDS) co-infected with active TB
2N(0)
120
RH TB-recovered with HIV-infection (pre-AIDS)
N(0)
120
AT HIV-Infected with AIDS symptoms co-infected with active TB
N(0)
120
Table 2: Initial conditions for the state variables of the TB-HIV/AIDS model
(1), borrowed from [25].
in Table 2, and minimizing the objective functional (2), i.e.,
J(u∗1(·), u
∗
2(·)) = min
Ω
J(u1(·), u2(·)).
The approach based on optimal control theory adopted in [25] allows to ob-
tain the optimal solution to the cost functional (2), which is defined from some
decision maker’s perspective by means of the constants w1 and w2. However,
the choice of the values of w1 and w2 requires some knowledge about the prob-
lem and the decision maker’s preferences, which often are not available in ad-
vance. Another disadvantage consists in the fact that a single optimal solution
to (2) does not provide all useful insights about the optimal strategies and
corresponding dynamics. A large range of alternatives remain unexplored and
the decision maker is limited in his/her options. In [25], numerical simulations
to the optimal control problem are performed using (w1, w2) = (25, 25) and
(w1, w2) = (250, 25). Both values are larger than one, which suggests that
they are adapted to the scale of the objectives. The choice of the values of
these parameters is not straightforward and there is no guarantee that the best
compromise solution has been obtained.
3.2 Multiobjective optimization
Our work addresses the optimal control problem for the TB-HIV/AIDS coinfec-
tion model (1) from a multiobjective perspective. A multiojective optimization
problem is formulated by decomposing the cost functional shown in (2) into
two components, representing different aspects that must be taken into consid-
eration when dealing with TB-HIV/AIDS. The problem of finding the optimal
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controls is defined as:
minimize f1(A(·), AT (·)) =
∫ T
0
[A(t) +AT (t)] dt,
f2(u1(·), u2(·)) =
∫ T
0
[
u21(t) + u
2
2(t)
]
dt,
subject to 0 ≤ u1(t) ≤ 0.95,
0 ≤ u2(t) ≤ 0.95,
u1(t) + u2(t) ≤ 0.95.
(3)
In the above formulation, the weights are absent and the two objectives represent
the medical and economical perspectives, respectively. This naturally reflects
the conflicting nature of the underlying decision making problem, hence, solving
(3) is interesting and challenging.
3.3 Scalarization
A traditional mathematical programming approach to solving a multiojective
optimization problem consists in transforming an original problem with multiple
objectives into a number of single-objective subproblems. This is referred to
as scalarization. The transformation is performed by means of a scalarizing
function with some user-defined parameters. A single Pareto optimal solution is
sought by optimizing each subproblem. Repeated runs with different parameter
settings for the scalarizing function are used to approximate multiple Pareto
optimal solutions.
Several approaches to scalarization have been developed. They differ in the
way the scalarizing function is formulated. The weighted sum method suggests
minimizing a weighted sum of the objectives [8]. The limitation of this method
is that solutions can only be obtained in convex regions of the Pareto front. On
the other hand, the ǫ-constraint method [10] suggests optimizing one objective
function and converting all other objectives into constraints by setting an upper
bound to each of them. This method can find solutions in both convex and non-
convex regions of the Pareto front. The method of weighted metrics [16] seeks
to minimize the distance between the feasible objective region and some refer-
ence point. This method is also known as compromise programming [32]. For
measuring the distance, a weighted Lp norm is utilized. When the value of p is
small, the method may fail to find solutions in nonconvex regions. When p =∞,
the method defines the weighted Chebyshev problem [2]. This problem consists
in minimizing the largest weighted deviation of one objective. By optimizing
the weighted Chebyshev problem, solutions from convex and nonconvex regions
can be generated. A major drawback is that even when the original MOP is dif-
ferentiable, the resulting single-objective problem is nondifferentiable. Weakly
Pareto optimal solutions can be also obtained [16]. A relaxed formulation of
the Chebyshev problem with differentiable scalarizing function is known as the
Pascoletti–Serafini scalarization [19]. Though, this method introduces one ad-
ditional variable and one constraint for each objective function. The normal
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boundary intersection [3] uses a hyperplane with evenly distributed points that
passes through the extreme points of the Pareto front. For each point on the
hyperplane, the method searches for the maximum distance along the normal
pointing toward the origin. The normal constraint method [15] suggests opti-
mizing one objective and employing an inequality constraint reduction of the
feasible space using the points on the hyperplane. However, there is no guaran-
tee that the solutions obtained by the normal boundary intersection and normal
constraint methods are Pareto optimal. A comparative analysis of the different
scalarization approaches on optimal control problems from epidemiology can be
found in [6, 7].
Motivated by the results recently obtained in [7] for a TB model, we adopt
here the ǫ-constraint method [10]. This method suggests optimizing one objec-
tive function while converting all other objectives into constraints by setting an
upper bound to each of them. The problem to be solved is of the following form:
minimize
x∈Ω
fl(x)
subject to fi(x) ≤ ǫi, ∀i ∈ {1, . . . ,m} ∧ i 6= l,
(4)
where the lth objective is minimized, the parameter ǫi represents an upper
bound of the value of fi and m is the number of objectives. The major reasons
for using this method are as follows. The ǫ-constraint method is able to find
solutions in convex and nonconvex regions of the Pareto optimal front. When all
the objective functions in the MOP are convex, problem (4) is also convex and
has a unique solution. For any given upper bound vector ǫ = {ǫ1, . . . , ǫm−1},
the unique solution of problem (4) is Pareto optimal [16]. Moreover, when
considering different scenarios in the model, the optimal solutions obtained for
the same values of ǫ can be used for comparison, as they will lie on the same
line in the objective space determined by the corresponding value of ǫ. This
characteristic is convenient and helpful for the analysis of the dynamics in the
TB-HIV/AIDS model.
4 Numerical simulations and discussion
This section presents and discusses numerical results for the optimal controls
using the multiobjective optimization approach. Moreover, possible scenarios
of applying the control strategies are investigated.
4.1 Experimental setup
The fourth-order Runge–Kutta method is used for numerically integrating sys-
tem (1). The control and state variables are discretized using 100 equally spaced
time intervals over the period [0, T ]. The integrals defining objective functions
in (3) are calculated using the trapezoidal rule.
Using the formulation (4), the first objective in (3) is minimized and the
second objective is set as the constraint bounded by the value of ǫ. The Pareto
10
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Figure 2: Trade-off curves for various periods of time.
front is discretized by defining 100 evenly distributed values of ǫ over the range of
the second objective, f2, which can be calculated as f
min
2 for (u1(·), u2(·)) ≡ 0
and fmax2 for u1(t) + u2(t) ≡ 0.95. It is worth noting that the ǫ-constraint
method does not need the information about the range of f1, which is not
known beforehand due to the presence of the constraint imposed on u1(t) +
u2(t), whereas the majority of methods discussed in Section 4 may need this
information. To solve the problems with different values of ǫ, the MATLAB R©
function fmincon with a sequential quadratic programming algorithm is used,
setting the maximum number of function evaluations to 50, 000. The behavior of
the dynamics in the TB-HIV/AIDS model are investigated for the cases when
both the controls u1 and u2 are applied separately and simultaneously. In
the following, the notation for resulting multiobjective optimization problems
(MOPs) will be as shown in Table 3: MOP1 refers to the case when u1 and u2
are applied simultaneously; MOP2 refers to the case when u1 is applied alone;
MOP3 refers to the case when u2 is applied alone. The components of the vector
f = (f1, f2)
T are as shown in (3).
MOP1 MOP2 MOP3
f(u1(·), u2(·)) f(u1(·)) f(u2(·))
Table 3: Different multiobjective optimization problems.
4.2 Results and discussion
Our study investigates optimal control strategies for different treatment periods.
The trade-off curves for the treatment scenarios presented in Table 3, considering
T ∈ {10, 30, 50}, are displayed in Figure 2. Overall, the larger period of study,
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the higher the number of individuals with AIDS and active TB. As expected,
reducing the amount of control measures leads to the increase in the number
of individuals with AIDS and active TB, whereas decrease in the number of
individuals with AIDS and active TB can be achieved though rising expenses
for treatment. These results clearly reflect the conflicting nature of the two
objectives. Also, it can be seen that an efficient range of the control policies is
limited, as starting from some point the reduction in the number of individuals
with AIDS and active TB is possible through exponential increase in expenses
for medication. Since available resources are often scarce, scenarios involving
high expenses may be practically unacceptable. All curves share similar features
and similar trends can be identified through analysis of the obtained solutions.
Due to these facts and space limitation, in what follows the obtained results are
discussed only for T = 10.
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Figure 3: Trade-off curves for T = 10.
Figure 3 shows the trade-off curves obtained for MOP1, MOP2 and MOP3,
corresponding to T = 10. As one can see, the three curves share a common point
in the objective space. This represents an economic perspective, i.e., there is no
treatment of TB and HIV/AIDS, the only focus is on saving money. Naturally,
this leads to an uncontrollable spread of the diseases and higher numbers of indi-
viduals with AIDS and active TB. As control policies start being implemented,
the response of (A+AT ) differs for the three considered cases. The best scenarios
from the medical perspective, i.e., when the maximum amounts of controls are
applied, are different. Interestingly, the lowest number of (A+AT ) is achieved
when only implementing u1(·) ≡ 0.95, which corresponds to the treatment of
patients for HIV/AIDS and TB together. In this case, scenarios resulting from
MOP1 and MOP2 are identical, being represented by the same point in the ob-
jective space. However, when optimal strategies involve the treatment for TB,
this allows to decrease the number of (A+AT ) in scenarios representing trade-off
12
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Figure 4: Dynamics of individuals with AIDS and active TB without controls.
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Figure 5: Dynamics of individuals with AIDS and active TB with maximum
controls.
between the economic and medical perspectives. It can be understood observing
all the intermediate solutions for MOP1 in Figure 3, which give a less value of f1
when comparing with solutions for MOP2 involving the same amount of control
measures. Though, treating patients only for TB appears to be an ineffective
approach when comparing with scenarios represented by MOP1 and MOP2, as
optimal solutions give significantly larger numbers of (A+AT ) along the whole
Pareto optimal region. For the extreme solutions, i.e., those corresponding to
the maximum and minimum amounts of controls applied though the period of
study, the dynamics of A, AT and (A+AT ) can be observed in Figures 4 and 5.
Without applying the controls, as discussed above, the corresponding dynamics
are identical for MOP1, MOP2 and MOP3 and are presented in Figures 4. This
scenario corresponds to the natural progression of the diseases. When only the
control u2 is applied, the number of A and AT , as well as their sum, are larger
than for cases when u1 and u1 + u2 are implemented. The dynamics for A and
AT are identical for MOP1 and MOP3, which are depicted in Figure 5(a).
To analyze intermediate scenarios, two solutions lying on intermediate re-
gions of the trade-off curves are selected. This is done as follows. The objective
space is divided by two horizontal lines corresponding to f2 = 3 and f2 = 6
(dashed lines in Figure 3). The intersections of these lines with the trade-off
curves give the three different solutions, with each of them corresponding to
MOP1, MOP2 and MOP3. These solutions are selected for discussing the dy-
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Figure 6: Controls and infected individuals for f2 = 3.
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Figure 7: Controls and individuals with AIDS and active TB for f2 = 6.
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namics of the diseases. These lines can be interpreted as the constraints defining
available resources for treatment. In turn, the selected solutions represent the
best treatment options in such circumstances, as they allow to achieve the lowest
values of f1. It is worth noting that the solutions on different curves, shown in
Figure 3, are identically distributed with respect to the values of f2 due to the
use of the ǫ-constrain method. Since MOP1–3 were solved for the same values
of ǫ, the corresponding solutions can be used for a fair comparison. Figure 6
presents the trajectories of the control variables and the dynamics of A and
AT for solutions corresponding to f2 = 3. From Figures 6(a)–6(c), it can be
seen that the changes of the total amount of control measures are similar. For
MOP1, the total control is composed of u1 and u2, which change differently
during the period of study. There is a peak in u2, taking place between the
third and forth years, after which it decreases. The dynamics of A and AT have
similar trajectories, as shown in Figures 6(d)–6(f). However, there is a minor
increase in A for MOP3 in the beginning of the forth year. Similar trends for
the control and state variables are observed in Figure 7. Though, the peak in
u2 occurs later with a higher value and the number of individuals with AIDS
and active TB is lower due to the large amount of medication.
Solutions obtained using multiobjective optimization can provide compre-
hensive insights about the optimal strategies and the diseases dynamics result-
ing from implementation of those strategies. Since visual representations can
help to better understand results and spot patterns that are not obvious at first,
in what follows each of the variables u1, u2, A and AT is defined as a function
of time and the objective to which it is conflicting. By doing so, it is possible
to provide the visualization of the entire optimal set of each variable. The set
of optimal values defines a surface. Slicing a surface gives the trajectory of the
corresponding dynamic over the period of study. Figure 8 shows the discrete
representations of surfaces defined by the controls over the whole Pareto optimal
region. On the other hand, the discrete representations of surfaces determined
by the responses of A and AT to optimal treatment strategies are illustrated in
Figure 9. The plots for other classes of human population can be obtained in a
similar way.
5 Conclusions
This paper investigates a mathematical model for TB-HIV/AIDS coinfection
recently proposed in [25]. A multiobjective formulation is proposed. This ap-
proach avoids the use of weight parameters and allows to obtain a wide range
of optimal control strategies, which offer useful information for effective de-
cision making. Two clearly conflicting objectives are defined for search the
optimal controls. The first objective reflects aspirations in controlling TB and
HIV/AIDS diseases, whereas the second objective aims to reduce the costs of
implementing control policies. The present study extends the previous work [25]
by the extensive analysis of the optimal control in the TB-HIV/AIDS coinfection
model, which enriches the knowledge about the model. Indeed, it is important
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Figure 8: Discrete representation of the optimal surface for u1, u2 and u1 + u2.
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not just to formulate a model but also to obtain useful information about the
process modeled. Our simulation results reveal the optimal treatment strategies
for TB and HIV infections and exposure to medication of different fractions of
the population. This can be used as an input for planning activities to fight
against TB and HIV. The choice of a final solution can be made including
the goals of public healthcare and available funds. The results here obtained
clearly demonstrate the usefulness and advantages of a multiobjective approach.
The presence of the clearly conflicting objectives gives rise to a set of optimal
solutions representing different trade-offs between them. Thus, each obtained
solution reveals different perspectives on coping with AIDS and active TB dis-
eases. The treatment of individuals infected by both HIV and TB can provide
the best effects, except for the extreme scenarios. As analyses showed, the set
of optimal trade-off solutions can offer to the decision maker an understand-
ing of all possible trends in applying the controls. Moreover, the dynamics of
different classes of individuals in the population appears as a response to the im-
plemented treatment measures. The ability to obtain, analyze and choose from
a set of alternatives, constitutes the major advantage of the proposed approach,
motivating its practical use in the process of planning intervention measures by
health authorities. As future work, we intend to study the effects of the param-
eters in the TB-HIV/AIDS coinfection model. Also, it would be interesting to
investigate the population dynamics resulting from implementation of optimal
treatment policies found by optimizing various types of objectives. Considering
L1 objectives in the optimal control problem is also the subject of future work.
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